← Leaderboards
James Doroshow
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
- Svetlana Pack$0
- John Glod$0
- Anna Roschke$0
- Stanley Lipkowitz$260,385
- Mark Raffeld$0
Others in their field
Top investigators on “Therapeutic Agents”
- David Heimbrook · Leidos Biomedical Research, Inc.$386,032,874
- Gregory H Reaman · National Childhood Cancer Foundation$247,684,034
- Leonard Freedman · Leidos Biomedical Research, Inc.$239,520,687
- Sharon A Nachman · Johns Hopkins University$213,337,729
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$208,842,121
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$197,687,122
Research focus
Therapeutic AgentsPharmaceutical PreparationsLaboratoriesOxidasesNadph OxidaseInhibitor/AntagonistGenesCell ProliferationMalignant Neoplasm Of Gastrointestinal TractSignal TransductionNeoplastic CellPlayProteinsOxidantsMediatingOxygenMolecularClinical TrialsProtein IsoformsSeriesColon CarcinomaPharmacodynamicsNovel TherapeuticsNadph Oxidase 1
Grant awards (44)
NADPH Oxidases as Novel Targets for Cancer Therapy$1,201,732
ZIA · FY2025 · CA · contact PI
Phase 0-1 Clinical Trials$647,086
ZIA · FY2025 · CA · contact PI
NADPH Oxidases as Novel Targets for Cancer Therapy$1,201,276
ZIA · FY2024 · CA · contact PI
Phase 0-1 Clinical Trials$646,840
ZIA · FY2024 · CA · contact PI
NADPH Oxidases as Novel Targets for Cancer Therapy$1,166,042
ZIA · FY2023 · CA · contact PI
Phase 0-1 Clinical Trials$627,868
ZIA · FY2023 · CA · contact PI
NADPH Oxidases as Novel Targets for Cancer Therapy$1,153,863
ZIA · FY2022 · CA · contact PI
Phase 0-1 Clinical Trials$621,311
ZIA · FY2022 · CA · contact PI
NADPH Oxidases as Novel Targets for Cancer Therapy$1,089,797
ZIA · FY2021 · CA · contact PI
Phase 0-1 Clinical Trials$586,813
ZIA · FY2021 · CA · contact PI
NADPH Oxidases as Novel Targets for Cancer Therapy$1,084,950
ZIA · FY2020 · CA · contact PI
Phase 0-1 Clinical Trials$584,204
ZIA · FY2020 · CA · contact PI
NADPH Oxidases as Novel Targets for Cancer Therapy$1,024,528
ZIA · FY2019 · CA · contact PI
Phase 0-1 Clinical Trials$551,668
ZIA · FY2019 · CA · contact PI
NADPH Oxidases as Novel Targets for Cancer Therapy$1,380,509
ZIA · FY2018 · CA · contact PI
Phase 0-1 Clinical Trials$743,351
ZIA · FY2018 · CA · contact PI
NADPH Oxidases as Novel Targets for Cancer Therapy$1,352,059
ZIA · FY2017 · CA · contact PI
Phase 0-1 Clinical Trials$728,032
ZIA · FY2017 · CA · contact PI
Phase 0-1 Clinical Trials$639,098
ZIA · FY2016 · CA · contact PI
NADPH Oxidase 1: A Novel Target for Colon Cancer Therapy$639,098
ZIA · FY2016 · CA · contact PI
Roles of NADPH Oxidase 5 and Dual Oxidase 2 in Cancer$547,798
ZIA · FY2016 · CA · contact PI
Roles of NADPH Oxidase 5 and Dual Oxidase 2 in Cancer$637,940
ZIA · FY2015 · CA · contact PI
NADPH Oxidase 1: A Novel Target for Colon Cancer Therapy$558,197
ZIA · FY2015 · CA · contact PI
Phase 01 Clinical Trials$398,712
ZIA · FY2015 · CA · contact PI
Roles of NADPH Oxidase 5 and Dual Oxidase 2 in Cancer$828,009
ZIA · FY2014 · CA · contact PI
NADPH Oxidase 1: A Novel Target for Colon Cancer Therapy$724,509
ZIA · FY2014 · CA · contact PI
Phase 01 Clinical Trials$517,506
ZIA · FY2014 · CA · contact PI
Roles of NADPH Oxidase 5 and Dual Oxidase 2 in Cancer$606,614
ZIA · FY2013 · CA · contact PI
NADPH Oxidase 1: A Novel Target for Colon Cancer Therapy$530,788
ZIA · FY2013 · CA · contact PI
Phase 01 Clinical Trials$379,135
ZIA · FY2013 · CA · contact PI
Roles of NADPH Oxidase 5 and Dual Oxidase 2 in Cancer$628,707
ZIA · FY2012 · CA · contact PI
NADPH Oxidase 1: A Novel Target for Colon Cancer Therapy$550,118
ZIA · FY2012 · CA · contact PI
Phase 01 Clinical Trials$392,941
ZIA · FY2012 · CA · contact PI
Roles of NADPH Oxidase 5 and Dual Oxidase 2 in Cancer$509,621
ZIA · FY2011 · CA · contact PI
NADPH Oxidase 1: A Novel Target for Colon Cancer Therapy$445,918
ZIA · FY2011 · CA · contact PI
Phase 01 Clinical Trials$318,513
ZIA · FY2011 · CA · contact PI
Roles of NADPH Oxidase 5 and Dual Oxidase 2 in Cancer$471,626
ZIA · FY2010 · CA · contact PI
NADPH Oxidase 1: A Novel Target for Colon Cancer Therapy$412,673
ZIA · FY2010 · CA · contact PI
Phase 01 Clinical Trials$294,767
ZIA · FY2010 · CA · contact PI
NADPH Oxidase 1: A Novel Target for Colon Cancer Therapy$542,167
ZIA · FY2009 · CA · contact PI
Roles of NADPH Oxidase 5 and Dual Oxidase 2 in Cancer$361,444
ZIA · FY2009 · CA · contact PI
Phase 01 Clinical Trials$301,204
ZIA · FY2009 · CA · contact PI
Roles of NADPH Oxidase 5 and Dual Oxidase 2 in Cancer$289,440
Z01 · FY2008 · CA · contact PI
Phase 01 Clinical Trials$96,480
Z01 · FY2008 · CA · contact PI